Table 4 Pooled outcomes at 1, 3, 6, and 12 months postoperatively and complication incidence rates
Outcomes | NO. of patients | Pooled effect | 95%CI | P | I2 | Exclude |
|---|---|---|---|---|---|---|
IPSS 1mo | 635 | -6.77 | (-8.24, -5.30) | < 0.001 | 77.50% | |
IPSS 3mos | 502 | -11.26 | (-12.52, -9.99) | < 0.001 | 63.40% | |
IPSS 6mos | 461 | -12.20 | (-13.00, -11.41) | < 0.001 | 19.80% | |
IPSS 12mos | 480 | -11.37 | (-12.53, -10.21) | < 0.001 | 58.90% | |
Qol 1mo | 612 | -1.41 | (-1.80, -1.03) | < 0.001 | 83.60% | |
Qol 3mos | 489 | -2.35 | (-2.65, -2.04) | < 0.001 | 67.90% | |
Pre-Qol 6mos | 448 | -2.61 | (-2.96, -2.25) | < 0.001 | 74.6% | |
Qol 6mos | 407 | -2.45 | (-2.62, -2.27) | < 0.001 | 35.60% | [11] |
Qol 12mos | 466 | -2.59 | (-2.92, -2.26) | < 0.001 | 76.80% | |
Qmax 1mo | 344 | 2.74 | (1.83, 3.66) | < 0.001 | 56.90% | |
Pre-Qmax 3mos | 314 | 4.54 | (2.6, 6.47) | < 0.001 | 89.60% | [8] |
Qmax 3mos | 312 | 5.28 | (4.54, 6.01) | < 0.001 | 44.30% | |
Qmax 6mos | 280 | 5.15 | (4.45, 5.85) | < 0.001 | 0 | |
Qmax 12mos | 251 | 5.26 | (4.53, 5.99) | < 0.001 | 28.70% | |
PVR 3mos | 231 | -12.42 | (-19.88, -4.96) | < 0.001 | 28.60% | |
PVR 6mos | 212 | -9.48 | (-19.72, 0.75) | 0.137 | 20.10% | |
PVR 12mos | 203 | -13.18 | (-24.32, -2.03) | < 0.001 | 18.70% | |
BPH II 3mos | 293 | -3.74 | (-4.60, -2.89) | < 0.001 | 76.80% | |
BPH II 6mos | 263 | -4.45 | (-4.83, -4.07) | < 0.001 | 48.20% | |
BPH II 12mos | 225 | -4.45 | (-5.10, -3.80) | < 0.001 | 58.50% | |
Pre-IIEF-EF 6mos | 179 | -0.05 | (-1.17, 1.67) | 0.953 | 74.50% | |
IIEF-EF 6mos | 175 | 0.37 | (-0.71, 1.45) | 0.439 | 15.90% | [8] |
IIEF-EF 12mos | 159 | 0.16 | (-0.91, 1.24) | 0.768 | 0 | |
MSHQ-EjD 1mo | 90 | 0.31 | (-0.53, 1.16) | 0.936 | 34.10% | |
MSHQ-EjD 3mos | 189 | 0.34 | (-0.26, 0.94) | 0.264 | 0 | |
Pre-MSHQ-EjD 6mos | 161 | 0.89 | (-0.51, 2.29) | 0.213 | 70.80% | |
MSHQ-EjD 6mos | 149 | 0.09 | (-0.55, 0.74) | 0.699 | 49.30% | [11] |
MSHQ-EjD 12mos | 146 | -0.03 | (-0.50, 0.96) | 0.728 | 49.30% | |
MSHQ-bother 1mo | 90 | -0.35 | (-0.67, -0.03) | 0.076 | 26% | |
MSHQ-bother 3mos | 189 | -0.36 | (-0.62, -0.11) | 0.027 | 45.10% | |
MSHQ-bother 6mos | 161 | -0.66 | (-1.23, -0.10) | 0.022 | 66.40% | |
MSHQ-bother 12mos | 147 | -0.75 | (-1.26, -0.25) | 0.004 | 51.60% | |
Adverse events | ||||||
Pre-Hematuria | 582 | 22% | (8%, 42%) | < 0.01 | 96.41% | |
Hematuria | 339 | 14% | (10%, 18%) | < 0.01 | 0 | |
Dysuria | 112 | 21% | (14%, 29%) | < 0.01 | 77.38% | |
Hematospermia | 42 | 10% | (2%, 22%) | < 0.01 | 89.47% | |
UTI | 544 | 7% | (3%, 11%) | < 0.01 | 68.38% | |
Urinary retention | 741 | 12% | (6%, 19%) | < 0.01 | 86.07% | |
Urinary urgency | 414 | 10% | (5%, 17%) | < 0.01 | 73.28% | |
Urinary frequency | 338 | 10% | (3%, 20%) | < 0.01 | 85.78% | |
Pelvic pain | 335 | 3% | (1%, 6%) | < 0.01 | 0 | |
Retreatment | 764 | 3% | (2%, 5%) | < 0.01 | 0 |